AAPS PharmSciTech

, Volume 13, Issue 2, pp 590–600 | Cite as

Preparation and Investigation of Sustained Drug Delivery Systems Using an Injectable, Thermosensitive, In Situ Forming Hydrogel Composed of PLGA–PEG–PLGA

  • Elham Khodaverdi
  • Farnaz Sadat Mirzazadeh Tekie
  • Seyed Ahmad Mohajeri
  • Fariba Ganji
  • Gholamhossein Zohuri
  • Farzin Hadizadeh
Research Article

Abstract

In situ gelling systems are very attractive for pharmaceutical applications due to their biodegradability and simple manufacturing processes. The synthesis and characterization of thermosensitive poly(d,l-lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–PLGA triblock copolymers as in situ gelling matrices were investigated in this study as a drug delivery system. Ring-opening polymerization using microwave irradiation was utilized as a novel technique, and the results were compared with those using a conventional method of polymerization. The phase transition temperature and the critical micelle concentration (CMC) of the copolymer solutions were determined by differential scanning calorimetry and spectrophotometry, respectively. The size of the micelles was determined with a light scattering method. In vitro drug release studies were carried out using naltrexone hydrochloride and vitamin B12 as model drugs. The rate and yield of the copolymerization process via microwave irradiation were higher than those of the conventional method. The copolymer structure and concentration played critical roles in controlling the sol–gel transition temperature, the CMC, and the size of the nanomicelles in the copolymer solutions. The rate of drug release could be modulated by the molecular weight of the drugs, the concentration of the copolymers, and their structures in the formulations. The amount of release versus time followed zero-order release kinetics for vitamin B12 over 25 days, in contrast to the Higuchi modeling for naltrexone hydrochloride over a period of 17 days. In conclusion, PLGA–PEG1500–PLGA with a lactide-to-glycolide ratio of 5:1 is an ideal system for the long-acting, controlled release of naltrexone hydrochloride and vitamin B12.

KEY WORDS

hydrogel naltrexone PLGA–PEG–PLGA thermosensitive triblock copolymer vitamin B12 

Notes

ACKNOWLEDGMENTS

The authors are grateful for the financial support provided by Mashhad University of Medical Sciences for this study. The results described in this paper were part of a Pharm D student’s thesis proposal.

REFERENCEs

  1. 1.
    Khodaverdi E, Rajabi O, Farhadi F, Jalali A, Mirzazadeh Tekie FS. Preparation and investigation of (N-isopropylacrylamide-acrylamide) membranes in temperature responsive drug delivery. Iran J Basic Med Sci. 2009;13:1–8.Google Scholar
  2. 2.
    Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abus Treat. 1997;14:19–22.CrossRefGoogle Scholar
  3. 3.
    Smith JB. Effects of repeated injections of naltrexone on antagonism of rate decreases by morphine in the pigeon. Pharmacol Biochem Behav. 1978;9:265–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Stromberg MF, Rukstalis MR, Mackler SA, Volpicelli JR, O’Brien CP. A comparison of the effects of 6-[beta] naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav. 2002;72:483–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Yin W, Akala EO, Taylor RE. Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. Int J Pharm. 2002;244:9–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Zalewska-Kaszubska J, Gorska D, Dyr W, Czarnecka E. Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav. 2006;85:155–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O’Malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry. 2007;61:1290–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Caraballo I, Melgoza LM, Alvarez-Fuentes J, Soriano MC, Rabasco AM. Design of controlled release inert matrices of naltrexone hydrochloride based on percolation concepts. Int J Pharm. 1999;181:23–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex “Gemini” prodrug of naltrexone for transdermal delivery. J Control Release. 2004;97:283–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54:127–35.PubMedCrossRefGoogle Scholar
  11. 11.
    McGregor C, Ali R, White JM, Thomas P, Gowing L. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend. 2002;68:5–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Iyer SS, Barr WH, Dance ME, Coleman PR, Karnes HT. A [‘]biorelevant’ system to investigate in vitro drug released from a naltrexone implant. Int J Pharm. 2007;340:104–18.PubMedCrossRefGoogle Scholar
  13. 13.
    Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30:2051–68.PubMedCrossRefGoogle Scholar
  14. 14.
    Lapham S, Forman R, Alexander M, Illeperuma A, Bohn MJ. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J Subst Abus Treat. 2009;36:1–6.CrossRefGoogle Scholar
  15. 15.
    Iyer SS, Barr WH, Karnes HT. A [‘]biorelevant’ approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm. 2007;340:119–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Ngo HTT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:23–8.CrossRefGoogle Scholar
  17. 17.
    Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005;79:351–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Tang Y, Singh J. Biodegradable and biocompatible thermosensitive polymer based injectable implant for controlled release of protein. Int J Pharm. 2009;365:34–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Kissel T, Li Y, Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv Drug Deliv Rev. 2002;54:99–134.PubMedCrossRefGoogle Scholar
  20. 20.
    Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm. 2007;332:107–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58:445–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Jeong JH, Park TG. Poly(l-lysine)-g–poly(d,l-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers. J Control Release. 2002;82:159–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Gupta M, Gupta AK. Hydrogel pullulan nanoparticles encapsulating pBUDLacZ plasmid as an efficient gene delivery carrier. J Control Release. 2004;99:157–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhong H, Matsui O, Xu K, Ogi T, Sanada J-i, Okamoto Y, Tabata Y, Takuwa Y. Gene transduction into aortic wall using plasmid-loaded cationized gelatin hydrogel-coated polyester stent graft. J Vasc Surg. 2009;50:1433–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Karoubi G, Ormiston ML, Stewart DJ, Courtman DW. Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells. Biomaterials. 2009;30:5445–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Weber LM, He J, Bradley B, Haskins K, Anseth KS. PEG-based hydrogels as an in vitro encapsulation platform for testing controlled [beta]-cell microenvironments. Acta Biomaterialia. 2006;2:1–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Anseth KS, Metters AT, Bryant SJ, Martens PJ, Elisseeff JH, Bowman CN. In situ forming degradable networks and their application in tissue engineering and drug delivery. J Control Release. 2002;78:199–209.PubMedCrossRefGoogle Scholar
  28. 28.
    He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release. 2008;127:189–207.PubMedCrossRefGoogle Scholar
  29. 29.
    Ruel-Gariépy E, Leroux J-C. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm. 2004;58:409–26.PubMedCrossRefGoogle Scholar
  30. 30.
    Kwon YM, Kim SW. New biodegradable polymers for delivery of bioactive agents. Macromol Symp. 2003;201:179–86.CrossRefGoogle Scholar
  31. 31.
    Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: in vitro and in vivo evaluation. Int J Pharm. 2008;352:58–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen S, Singh J. Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation. Int J Pharm. 2005;295:183–90. doi: 183.PubMedCrossRefGoogle Scholar
  33. 33.
    Qiao M, Chen D, Ma X, Liu Y. Injectable biodegradable temperature-responsive PLGA–PEG–PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm. 2005;294:103–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Ghahremankhani AA, Dorkoosh F, Dinarvand R. PLGA–PEG–PLGA tri-block copolymers as an in-situ gel forming system for calcitonin delivery. Polym Bull. 2007;59:637–46.CrossRefGoogle Scholar
  35. 35.
    Zentner GM, Rathi R, Shih C, McRea JC, Seo M-H, Oh H, Rhee BG, Mestecky J, Moldoveanu Z, Morgan M, Weitman S. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release. 2001;72:203–15.PubMedCrossRefGoogle Scholar
  36. 36.
    Pratoomsoot C, Tanioka H, Hori K, Kawasaki S, Kinoshita S, Tighe PJ, Dua H, Shakesheff KM, Rose FRAJ. A thermoreversible hydrogel as a biosynthetic bandage for corneal wound repair. Biomaterials. 2008;29:272–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Salehi R, Nowruzi K, Entezami AA, Asgharzadeh V, Davaran S. Thermosensitive polylactide–glycolide delivery systems for treatment of narcotic addictions. Polym Adv Technol. 2009;20:416–22.CrossRefGoogle Scholar
  38. 38.
    Yu L, Chang GT, Zhang H, Ding JD. Injectable block copolymer hydrogels for sustained release of a PEGylated drug. Int J Pharm. 2008;348:95–106.PubMedCrossRefGoogle Scholar
  39. 39.
    Chen S, Pieper R, Webster DC, Singh J. Triblock copolymers: synthesis, characterization, and delivery of a model protein. Int J Pharm. 2005;288:207–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Jeong B, Han Bae Y, Wan Kim S. Biodegradable thermosensitive micelles of PEG–PLGA–PEG triblock copolymers. Colloids Surf B: Biointerfaces. 1999;16(1–4):185–93.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2012

Authors and Affiliations

  • Elham Khodaverdi
    • 1
    • 6
  • Farnaz Sadat Mirzazadeh Tekie
    • 2
  • Seyed Ahmad Mohajeri
    • 3
  • Fariba Ganji
    • 4
  • Gholamhossein Zohuri
    • 5
  • Farzin Hadizadeh
    • 2
  1. 1.Department of Pharmaceutics, School of PharmacyMashhad University of Medical SciencesMashhadIran
  2. 2.Biotechnology Research Center, School of PharmacyMashhad University of Medical SciencesMashhadIran
  3. 3.Pharmaceutical Research Center, School of PharmacyMashhad University of Medical SciencesMashhadIran
  4. 4.Biotechnology Group, Faculty of Chemical EngineeringTarbiat Modares UniversityTehranIran
  5. 5.Department of Chemistry, Faculty of ScienceFerdowsi UniversityMashhadIran
  6. 6.Drug Delivery Research Center, School of PharmacyMashhad University of Medical SciencesMashhadIran

Personalised recommendations